Gender Differences in Adverse Drug Reactions during HAART Therapy in HIV/AIDS Patients at a Tertiary Care Hospital Penang, MalaysiaKashif Ullah Khan1*, Amer Hayat Khan1, Syed Azhar Sulaiman1, Chow Ting Soo2, Syed Imran Ahmed3, Abdul Haseeb1,4 and Hani Saleh Faidah5
- *Corresponding Author:
- Kashif Ullah Khan, PhD
Department of Clinical Pharmacy
School of Pharmaceutical Sciences
Universiti Sains Malaysia, 11800 Penang, Malaysia
Fax: 00604 657 0017
E-mail: [email protected]; [email protected]
Received date: July 31, 2017; Accepted date: August 07, 2017; Published date: August 14, 2017
Citation: Khan KU, Khan AH, Sulaiman SA, Soo CT, Ahmed SI, et al. (2017) Gender Differences in Adverse Drug Reactions during HAART Therapy in HIV/AIDS Patients at a Tertiary Care Hospital Penang, Malaysia. J AIDS Clin Res 8:720. doi:10.4172/2155-6113.1000720
Copyright: © 2017 Khan KU, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims and objective: Current study is aimed to explore and observe adverse drug reactions occurrence of antiretroviral therapy and to examine the gender differences in treatment outcomes of HIV/AIDS patients during HAART therapy. Method: An observational retrospective study of all patients on HAART therapy diagnosed with HIV infection from January 2007 to December 2012 was conducted at infectious disease department of Hospital Pulau Pinang, Malaysia. Patients socio-demographic, clinical and laboratory data was retrieved via self developed validated data collection form. Results: Out of 743 patients 571 (76.8%) were male and 172 (23.1%) were female patients. A total number of 425 (57.2%) adverse drug reactions were reported among which 311 (73.1%) occurred in males and 114 (26.8%) in female patients, with a significant statistical relationship (p=0.02, OR=1.21). Out of total ADRs (57.2%) observed in both genders, a significant association was observed in Lipodystrophy (p=0.05), anemia (p=0.02), Peripheral Neuropathy (p=0.02) and pancreatitis (p=0.01). A total of 455 (79.6%) male and 139 (80.8%) female patients have improvement in CD4 cells count at the final follow up, a significant association (p=0.05) was observed among the mode of transmission and treatment outcome. Conclusion: Overall, the ADRs observed in both gender emphasize the importance of developing safer HAART regimens and managing these adverse effects in a timely manner in order to avoid long-term health consequences.